Search Results
You are looking at 1 - 2 of 2 items for
- Author: Enrico Solcia x
- Refine by access: All content x
Search for other papers by Nora Sahnane in
Google Scholar
PubMed
Search for other papers by Daniela Furlan in
Google Scholar
PubMed
Search for other papers by Matilde Monti in
Google Scholar
PubMed
Search for other papers by Chiara Romualdi in
Google Scholar
PubMed
Search for other papers by Alessandro Vanoli in
Google Scholar
PubMed
Search for other papers by Emanuela Vicari in
Google Scholar
PubMed
Search for other papers by Enrico Solcia in
Google Scholar
PubMed
Search for other papers by Carlo Capella in
Google Scholar
PubMed
Search for other papers by Fausto Sessa in
Google Scholar
PubMed
Search for other papers by Stefano La Rosa in
Google Scholar
PubMed
Gastroenteropancreatic (GEP) neuroendocrine carcinomas (NECs) and mixed adenoneuroendocrine carcinomas (MANECs) are heterogeneous neoplasms characterized by poor outcome. Microsatellite instability (MSI) has recently been found in colorectal NECs showing a better prognosis than expected. However, the frequency of MSI in a large series of GEP-NEC/MANECs is still unknown. In this work, we investigated the incidence of MSI in GEP-NEC/MANECs and characterized their clinicopathologic and molecular features. MSI analysis and immunohistochemistry for mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) were performed in 89 GEP-NEC/MANECs (six esophageal, 77 gastrointestinal, three pancreatic, and three of the gallbladder). Methylation of 34 genes was studied by methylation-specific multiplex ligation probe amplification. Mutation analysis of BRAF and KRAS was assessed by PCR-pyrosequencing analysis. MSI was observed in 11 NEC/MANECs (12.4%): seven intestinal and four gastric. All but two MSI-cases showed MLH1 methylation and loss of MLH1 protein. The remaining two MSI-cancers showed lack of MSH2 or PMS2 immunohistochemical expression. MSI-NEC/MANECs showed higher methylation levels than microsatellite stable NEC/MANECs (40.6% vs 20.2% methylated genes respectively, P<0.001). BRAF mutation was detected in six out of 88 cases (7%) and KRAS mutation was identified in 15 cases (17%). BRAF mutation was associated with MSI (P<0.0008), while KRAS status did not correlate with any clinicopathologic or molecular feature. Vascular invasion (P=0.0003) and MSI (P=0.0084) were identified as the only independent prognostic factors in multivariate analysis. We conclude that MSI identifies a subset of gastric and intestinal NEC/MANECs with distinct biology and better prognosis. MSI-NEC/MANECs resemble MSI-gastrointestinal adenocarcinomas for frequency, molecular profile and pathogenetic mechanisms.
Search for other papers by Massimo Milione in
Google Scholar
PubMed
Search for other papers by Patrick Maisonneuve in
Google Scholar
PubMed
Search for other papers by Alessio Pellegrinelli in
Google Scholar
PubMed
Search for other papers by Federica Grillo in
Google Scholar
PubMed
Search for other papers by Luca Albarello in
Google Scholar
PubMed
Search for other papers by Paola Spaggiari in
Google Scholar
PubMed
Search for other papers by Alessandro Vanoli in
Google Scholar
PubMed
Search for other papers by Giovanna Tagliabue in
Google Scholar
PubMed
Search for other papers by Eleonora Pisa in
Google Scholar
PubMed
Search for other papers by Luca Messerini in
Google Scholar
PubMed
Clinical Research Lab (CRAB), Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Search for other papers by Giovanni Centonze in
Google Scholar
PubMed
Search for other papers by Frediano Inzani in
Google Scholar
PubMed
Search for other papers by Aldo Scarpa in
Google Scholar
PubMed
Search for other papers by Mauro Papotti in
Google Scholar
PubMed
Search for other papers by Marco Volante in
Google Scholar
PubMed
Search for other papers by Fausto Sessa in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
University of Milan, School of Medicine, Milan, Italy
Search for other papers by Giancarlo Pruneri in
Google Scholar
PubMed
Search for other papers by Guido Rindi in
Google Scholar
PubMed
Search for other papers by Enrico Solcia in
Google Scholar
PubMed
Search for other papers by Stefano La Rosa in
Google Scholar
PubMed
Search for other papers by Carlo Capella in
Google Scholar
PubMed
Mixed adenoneuroendocrine carcinomas (MANECs) are composed of a poorly differentiated neuroendocrine carcinoma (NEC) and a non-neuroendocrine (non-NEC) neoplastic epithelial component, each representing at least 30% of the tumor. At present, prognostic factors for MANECs remain largely unexplored. We investigated the clinical-pathologic features of a large multicenter series of digestive system MANECs. Surgical specimens of 200 MANEC candidates were centrally reviewed; diagnosis was confirmed in 160 cases. While morphology, proliferation (mitotic count (MC), Ki67 index) and immunophenotype (p53, SSTR2a, beta-Catenin, Bcl-2, p16, Rb1, ALDH, mismatch repair proteins and CD117) were investigated separately in both components, genomic (TP53, KRAS, BRAF) alterations were searched for on the entire tumor. Data were correlated with overall survival (OS). MANEC sites were: 92 colorectal, 44 gastroesophageal and 24 pancreatobiliary. Median OS was 13.2 months. After adjustment for primary site, Ki67 index of the NEC component (but not of the non-NEC component) was the most powerful prognostic marker. At multivariable analysis, patients with Ki67 ≥ 55% had an 8-fold risk of death (hazard ratio (HR) 7.83; 95% confidence interval (CI) 4.17–14.7; P < 0.0001) and a median OS of 12.2 months compared to those with Ki67 < 55% (median OS 40.5 months). MC (HR 1.51; 95% CI 1.03–2.20, P = 0.04) was a weaker prognostic index. Colorectal primary site (HR 1.60; 95% CI 1.11–2.32; P = 0.01) was significantly associated with poorer survival. No single immunomarker, in either component, was statistically significant. This retrospective analysis of a large series of digestive system MANECs, showed that the NEC component, particularly its Ki67 index, was the main prognostic driver.